Artificial intelligence-guided detection of tumour peptides for immunotherapy against therap y-resistant cutaneous squamous cell carcinoma (CSCC)

Collaborator

North Queensland has the highest incidence of CSCC worldwide, which has a huge impact on the local population. With a high tumour mutational burden, CSCC is responsive to immunotherapy, however therapy-resistant CSCC presents a significant challenge. This project aims to detect and select tumour-specific peptides for immunotherapy in patients with therapy-resistant CSCC. The focus on tumour-specific peptides aims to ensure that these peptides are unique to tumour cells, thereby minimising the risk of triggering autoimmunity in treated patients. This innovative approach seeks to enhance the precision and safety of immunotherapies by targeting tumour-specific antigens.

01 Jan 2025 - 30 Dec 2026

N/A